MODIFIED PROTEINS

Methods and compositions relating to improved lentiviral vectors and their applications

Procoagulant peptides

MODIFIED FACTOR VIII

Methods for treating a hemostasis related disorder using activated forms of Factor V

Inhibition of the Anti-FVIII Immune Response

EXPRESSION OF SOLUBLE FACTOR VIII PROTEINS IN BACTERIA

Expression of soluble therapeutic proteins

Affinity adsorbents for Factor VIII and von Willebrand's Factor

Crystal structure of human factor VIII and uses thereof

Immunoadsorption of anti-von Willebrand factor cleaving protease antibodies

Modified recombinant factor VIII and von Willebrand factor and methods of use

Transgenic Non-Human Animals Expressing Human Blood Clotting Factors and Uses Thereof

Pegylated factor VII glycoforms

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Catalytic anti-factor VIII allo-antibodies

Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS

METHODS FOR TESTING ANTI-THROMBOTIC AGENTS

Process for obtaining a concentrate of Von Willebrand factor or a complex of factor VII/Von Willebrand factor and use of the same

Methods of treating using hormone-albumin fusion proteins

Cell culture processes

OPTIMIZED MESSENGER RNA

Recombinant factor VIII having reduced inactivation by activated protein C

Recombinant factor VIII having increased stability

Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells

MATRIX-TARGETED FUSION POLYPEPTIDES FOR TISSUE REGENERATION AND WOUND HEALING

Method for improved isolation of recombinantly produced proteins

Proteolytically cleavable fusion proteins with high molar specific activity

OPTIMIZED MESSENGER RNA

Methods of preparing pharmaceutical compositions for treatment of factor Vlll associated disorders and methods of use

OPTIMIZED MESSENGER RNA

Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

Modified Cdna for High Expression Levels of Factor VIII and Its Derivatives

Factor IX: remodeling and glycoconjugation of factor IX

COMPOSITIONS AND METHODS FOR ENHANCING FACTOR VIII HEAVY CHAIN SECRETION

Devices and methods for integrated continuous manufacturing of biological molecules

Proteolytically cleavable fusion proteins with high molar specific activity

Methods for chemically synthesizing immunoglobulin chimeric proteins

Transgene delivering retrovirus targeting collagen exposed at site of tissue injury

von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

Blood Coagulation FVIII Analogues

Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII

Transformed and method for mass-production of LK8 protein using the same

Method for reducing the immune response to a biologically active protein

Medium for the protein-free and serum-free cultivation of cells

Purification of Factor Xlll Polypeptides From Biological Materials

Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV

OPTIMIZED MESSENGER RNA

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor

Factor VIII: Remodeling and glycoconjugation of factor VIII

Method of Producing Factor VIII Proteins by Recombinant Methods

Pegylated Factor VII Glycoforms

Process for isolation of plasma or serum proteins

Stabilized proteins with engineered disulfide bonds

Virally-safe factor VIII with a low content of higher multimers

Recombinant factor VIII having increased specific activity

Pegylated factor VIII

Hemostatically active vWF-containing preparation and process for the preparation thereof

FACTOR VIII COMPOSITIONS AND METHODS

FACTOR VIII COMPOSITIONS AND METHODS

Factor VIII separation

Oligopeptide-free cell culture media

Lentiviral vectors featuring liver specific transcriptional enhancer and methods of using same

Immunoglobulin chimeric monomer-dimer hybrids

Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use

RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOPHILIA A

Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same

Production of a von Willebrand factor preparation having a high specific activity

Modified factor VIII

Substrate polyeptides for von Willebrand factor cleaving protease ADAMTS-13

Erythropoietin: remodeling and glycoconjugation of erythropoietin

Crystal of a truncated protein construct containing a coagulation factor VIII C2 domain in the presence or absence of a bound ligand and methods of use thereof

Inactivation resistant factor VIII

Remodeling and glycoconjugation of peptides

Vectors

Method for linking molecular substances

Drug for treating hemophilia and method of treating hemophilia using the same

Method for improving recovery yield in protein purification with gel filtration chromatography

Binding molecules for human factor VIII and factor VIII-like proteins

Fvii or fviia variants having increased clotting activity

Factor VIII polypeptide having factor VIII:C activity

Polymer-factor VIII-von Willebrand factor-conjugates

Protein complexes having factor VIII:C activity and production thereof

Site-directed modification of FVIII

Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

Antigenic fragments of human factor VIII polypeptides

Process for the preparation of a von Willebrand (FvW) factor concentrate by chromatography and a FvW concentrate thus obtainable

Expression of proteins in cord blood-derived endothelial cells

Inactivation resistant factor VIII

Adeno-associated vector compositions for expression of Factor VIII

Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

Modified factor VIII

Method of delivering therapeutic agents to site of tissue injury

Factor VIII/vWF-complex and methods of purifying same

Methods of treatment with interferson and albumin fusion protein

Transgenic mammal secreting B-domain deleted human FVII in its milk

Stable factor VIII/von willebrand factor complex

Filtration

Modulation of platelet adhesion based on the surface-exposed beta-switch loop of platelet glycoprotein IB-alpha

Methods for producing Factor VIII proteins

Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same

Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes

Stabilization of protein preparations

Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use

Pegylated factor VII glycoforms

Pharmaceutical compositions of glycoconjugates

Factor VIII compositions and methods

Factor IX: remolding and glycoconjugation of Factor IX

Modified factor VIII

Factor VII polypeptide having factor VII:C activity

Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells

Matrix-targeted fusion polypeptides for tissue regeneration and wound healing

Immunoglobulin chimeric monomer-dimer hybrids

Methods for chemically synthesizing immunoglobulin chimeric proteins

Method of complexing a protein by the use of a dispersed system and proteins thereof

Glycosylated, low antigenicity, low immunogenicity factor VIII

Vector co-expressing truncated von Willebrand factor and factor VIII